|View printer-friendly version|
|BrainStorm Announces Publication of NurOwn® Autism Research Study|
The publication reported that transplantation of mesenchymal stem cells (MSC) induced to secrete neurotrophic factors (MSC-NTF cells, NurOwn®) in the BTBR mouse model of autism demonstrated significant long-term improvements in autistic behavior in the BTBR mice compared to MSC treated and to untreated BTBR mice.
A single NurOwn® dose improved social behavior communication skills, and cognitive flexibility, an improvement that was not observed with MSC treatment, and reduced stereotypic repetitive behaviors in the BTBR mice six months post transplantation, a reduction that was only observed for a shorter period (one month) following MSC transplantation.
The authors concluded that NurOwn® treatment markedly reduced autistic behavior in BTBR mice for an extended period after a single cell transplantation, and that NurOwn® is superior to MSC treatment, as demonstrated in its beneficial effect on communication skills and stereotypic behavior. They noted that this was the first study to show an improvement across all autistic like behavioral phenotypes that can be measured in mice and the first to demonstrate a long-lasting effect of a single treatment for six months.
"These findings are especially encouraging because of the lack of effective medical treatments available for autism and the enormous impact this condition has on patients and their families," said
According to the
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult mesenchymal stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-announces-publication-of-nurown-autism-research-study-300441786.html